Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

PURPOSE: New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Wierda, William G., Kipps, Thomas J., Mayer, Jiří, Stilgenbauer, Stephan, Williams, Cathy D., Hellmann, Andrzej, Robak, Tadeusz, Furman, Richard R., Hillmen, Peter, Trneny, Marek, Dyer, Martin J.S., Padmanabhan, Swami, Piotrowska, Magdalena, Kozak, Tomas, Chan, Geoffrey, Davis, Randy, Losic, Nedjad, Wilms, Joris, Russell, Charlotte A., Österborg, Anders
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979101/
https://ncbi.nlm.nih.gov/pubmed/20194866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.3187
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados